Thread by @Berninini

So #twitterx doesn't throw me in Twitter jail, here are 10 #ASH21 abstracts...as HARRY POTTER characters.

I couldn't decide if I should rank based on "impactful" or "practice changing", so these are some that I think everyone should *read carefully*, and I tried to make it fun!

1. POLARIX = Severus Snape ash.confex.com/ash/2021/webpr… Why? Because of how controversial this is, and also this is a well done study. Should we change practice based on a drug without an OS or QOL benefit? I argue no. Nagini, kill. #lymsm

2. GRAAPH-2014 Study = Dudley Dursley ash.confex.com/ash/2021/webpr… Removing HiDAC from chemo in Ph+ ALL worsened outcomes. A cautionary tale that we can’t get greedy and we need RCT data like this as we “de-intensify” regimens in ALL with novel therapies like blin, TKIs, etc. #leusm

3. GMALL 08/2013 = Hermoine Granger ash.confex.com/ash/2021/webpr… What's not to love? ❤️Risk-adapted strategy to incorporate novel tx ALL in highest risk pts, dose-adjusted PEG for risk factors. Smart, great looking trial design has to be my favorite character!

4. Time spent at home with HMA + ven therapy = Dobby, the house elf ash.confex.com/ash/2021/webpr… Small, but mighty, Dobby (like this abstract) is all about caring. I want to see more research like this on outcomes important to patients and on the patient experience. #leusm

5. HD MTX international retrospective study of 2300 high-risk DLBCL patients = Bellatrix Lestrange ash.confex.com/ash/2021/webpr… She's crazy, and it's crazy it took so long to figure out HD MTX prophy doesn't work for these pts. Hopefully we end this practice like Molly Weasley did her

6. SEQUOIA - Zanubrutinib vs. BR in newly diagnosed CLL = Neville Longbottom ash.confex.com/ash/2021/webpr… Good they compared to BR instead of like chlorambucil or something, I guess. Meh. Ok. No OS benefit, but more BTKi data upfront! Woo. Basically how I feel about Neville.

7,8,9. All 3 CAR-T trials (Belinda, Transform, Zuma) = The 3 Deathly Hallows Brothers. Why? Because we will learn much from the lessons/tale in analyzing these data - they could make us powerful...or destroy us. Can we solve the riddle? Should we move CAR-T to 2L? Much to digest!

10. Aza vs. Aza + Gilteritinib = Gilderoy Lockhart ash.confex.com/ash/2021/webpr… Lots of hype, stylish looks, ultimately does nothing helpful. Just use HMA+ven in these patients. Triplets? Not sure yet, need RCT data! #leusm

11. Note the absence of CPX-351 on this list. Why are we still using Vyxeos? Vyxeos is Voldemort. Honorable mention to the many real-world comparisons of HMA/ven or HiDAC based regimens to CPX including ash.confex.com/ash/2021/webpr… ash.confex.com/ash/2021/webpr… ash.confex.com/ash/2021/webpr…

There were so many great abstracts and it was a phenomenal #ASH21! So happy I got to meet so many of you in person! Cheers for the next one!

Also, I saw soooo much PharmD research there! Very proud of that 😊👏🏻 Well done all!

The partnership of PharmDs with our physicians and other researchers is *vital* to future success in improving patient outcomes!